CD44 and neoplasm: The enhanced antitumor activity was most likely due to the targeted delivery of DOX–CDC-H to the tumor site via CD44 targeting and the efficient aggregation of CDC-H nanoparticles for passive targeting, in agreement with the previous results from MTT.